Biosimilar firm Coherus BioSciences Inc. succeeded under its inter partes review (IPR) petition in convincing the Patent Trial and Appeal Board (PTAB) of the US Patent & Trademark Office (US PTO) there was a reasonable likelihood a dosing methods patent held by AbbVie Inc. on its main moneymaker Humira (adalimumab) was invalid and won the right to challenge it in a trial.
The PTAB's decision to institute a trial on five claims of AbbVie's patent 8,889,135-B2 – the '135 patent – sent...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
